As biologics manufacturing grows more complex, the right technology transfer strategy can make all the difference. Explore how this MSAT-led approach helps ensure seamless transfers, robust process performance, and long-term commercial success.
Small-scale downstream studies are proving to be powerful tools for de-risking development and strengthening manufacturing readiness. Discover how a structured, data-driven approach can support successful scale-up, regulatory compliance, and reliable commercial production.
Learn how we're expanding our global manufacturing footprint, strengthening dual-sourcing capabilities across the U.S. and Korea, and advancing our long-term vision for next-generation biologics and advanced therapy manufacturing.
Samsung Biologics is a fully integrated, end-to-end CDMO partner offering seamless development and manufacturing services from cell line development to final aseptic fill/finish for biologics. Keeping the highest standards of commercialization in mind, we continue to expand our development portfolio and continue to offer the most optimized service to fit clients' needs. Our facilities are cGMP compliant with bioreactor sizes ranging from small to large scale, enabling us to better serve the various needs of our clients and to meet growing biomanufacturing demands.
